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Celecoxib exerts protective effects 
in the vascular endothelium via 
COX-2-independent activation of 
AMPK-CREB-Nrf2 signalling
Fahad Al-Rashed1,2, Damien Calay1, Marie Lang1, Clare C. Thornton1, Andrea Bauer1,  
Allan Kiprianos1, Dorian O. Haskard1, Anusha Seneviratne1, Joseph J. Boyle  1,  
Alex H. Schönthal3, Caroline P. Wheeler-Jones4 & Justin C. Mason1
Although concern remains about the athero-thrombotic risk posed by cyclo-oxygenase (COX)-2-
selective inhibitors, recent data implicates rofecoxib, while celecoxib appears equivalent to NSAIDs 
naproxen and ibuprofen. We investigated the hypothesis that celecoxib activates AMP kinase (AMPK) 
signalling to enhance vascular endothelial protection. In human arterial and venous endothelial 
cells (EC), and in contrast to ibuprofen and naproxen, celecoxib induced the protective protein 
heme oxygenase-1 (HO-1). Celecoxib derivative 2,5-dimethyl-celecoxib (DMC) which lacks COX-2 
inhibition also upregulated HO-1, implicating a COX-2-independent mechanism. Celecoxib activated 
AMPKα(Thr172) and CREB-1(Ser133) phosphorylation leading to Nrf2 nuclear translocation. Importantly, 
these responses were not reproduced by ibuprofen or naproxen, while AMPKα silencing abrogated 
celecoxib-mediated CREB and Nrf2 activation. Moreover, celecoxib induced H-ferritin via the same 
pathway, and increased HO-1 and H-ferritin in the aortic endothelium of mice fed celecoxib (1000 ppm) 
or control chow. Functionally, celecoxib inhibited TNF-α-induced NF-κB p65(Ser536) phosphorylation by 
activating AMPK. This attenuated VCAM-1 upregulation via induction of HO-1, a response reproduced 
by DMC but not ibuprofen or naproxen. Similarly, celecoxib prevented IL-1β-mediated induction of 
IL-6. Celecoxib enhances vascular protection via AMPK-CREB-Nrf2 signalling, a mechanism which may 
mitigate cardiovascular risk in patients prescribed celecoxib. Understanding NSAID heterogeneity and 
COX-2-independent signalling will ultimately lead to safer anti-inflammatory drugs.
The non-steroidal inflammatory drugs (NSAIDs), which include traditional non-selective NSAIDS (nsNSAIDs) 
and cyclo-oxygenase-2 selective NSAIDs (COXIBs), are widely prescribed and effective for symptom control in 
chronic diseases such as osteoarthritis (OA), ankylosing spondylitis and rheumatoid arthritis (RA). Although 
the principle cardiovascular and gastrointestinal side-effects are well recognised1, particular concern regarding 
COXIB-associated atherothrombotic risk persists2. Concern began with the publication of the APPROVE trial 
which reported increased thrombotic cardiovascular events in patients taking rofecoxib3. Rofecoxib was subse-
quently withdrawn and the concept of a COXIB class effect developed2,4. However, subsequent data has shown 
that there is considerable heterogeneity amongst nsNSAIDs and COXIBs, suggesting they should be consid-
ered as individual drugs rather than classes5–7. A recent meta-analysis investigated the most widely prescribed 
nsNSAIDs and COXIBs and their cardiovascular risk data8. The study confirmed the significant cardiovascular 
risk associated with rofecoxib. Importantly however, when rofecoxib data were removed from the COXIB group 
no difference in cardiovascular risk between COXIBs and nsNSAIDs remained, demonstrating skewing of the 
COXIB data by rofecoxib8. Furthermore, cardiovascular risk associated with celecoxib did not differ significantly 
from placebo. Celecoxib therapy conferred a lower risk of stroke and myocardial infarction than nsNSAIDs (other 
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than naproxen)8, as previously shown in the CLASS trial9. The importance of the disease context and drug indi-
viduality is also revealed by studies of NSAID use in inflammatory arthritis where drug-associated cardiovascular 
risk is low, less than that seen in the control population, and principally associated with rofecoxib or diclofenac 
therapy10,11. Likewise, in patients with ankylosing spondylitis celecoxib therapy at an average daily dose of 300 mg 
was negatively associated with coronary artery disease12.
As a consequence of these observations, subsequent studies have compared the side-effects of individual 
NSAIDs in more detail. The risk of admission to hospital for heart failure was increased by etorocoxib, rofecoxib 
and seven nsNSAIDs but not by celecoxib at commonly used doses13. The Standard care versus Celecoxib 
Outcome Trial (SCOT) studied patients free of cardiovascular disease and compared cardiovascular safety in 
those prescribed continued nsNSAID therapy with those switched to celecoxib. The cardiovascular event rate was 
low (<1 per 100 patient years) and comparable between the two groups14. Finally, the recently reported ten year 
Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) 
trial enrolled 24,081 patients with RA or OA with established or significant risk of cardiovascular disease15. 
Although drug discontinuation rates were high and some caveats remain, the trial showed celecoxib to be non-
inferior to ibuprofen and naproxen with respect to cardiovascular risk, and to exhibit significantly improved 
gastrointestinal safety than either nsNSAID15,16.
The differences seen between individual nsNSAIDs and COXIBs, both within and between the two classes, led 
to the search for COX-2-independent actions of these drugs17. These have been identified in a variety of cell types. 
In vascular endothelial cells (EC) celecoxib inhibited TNF-α-mediated induction of tissue factor by minimising 
JNK mitogen-activated protein kinase (MAPK) activity, a response not seen with rofecoxib18. The growth inhib-
itory effect of celecoxib reflected inhibition of cyclin-dependent kinases19. Similarly, celecoxib but not rofecoxib 
increased heme oxygenase-1 (HO-1) expression and activity in human endothelium via changes in redox signal-
ling20, a mechanism also identified in macrophages and vascular smooth muscle cells21.
These data led us to explore the role of COX-2 in celecoxib-mediated responses and to investigate COX-
2-independent signalling in the vascular endothelium. We now report that celecoxib activates a novel 
anti-inflammatory AMPK-CREB-Nrf2-dependent pathway. This response was COX-2-independent and was not 
reproduced by the nsNSAIDs ibuprofen or naproxen. Activation of AMPK-CREB-Nrf2 signalling enhances EC 
protection and we propose that it plays a significant role in modifying cardiovascular risk.
Results
Celecoxib-mediated induction of HO-1 is COX-2-independent. Exposure of HUVEC to celecoxib 
resulted in the induction of HO-1, with a 3-fold increase in HO-1 mRNA seen after 16 and 24 h treatment, along 
with a corresponding concentration-dependent increase in protein (p < 0.01) (Fig. 1). This HO-1 response was 
used to interrogate the molecular mechanism underpinning vasculoprotective actions of celecoxib. Celecoxib 
derivative 2,5-dimethyl-celecoxib (DMC) was initially used to investigate the role of COX-2 inhibition. DMC 
Figure 1. Celecoxib induces HO-1 in human endothelium. HUVECs were treated with celecoxib (up to 
10 µM) or vehicle alone for up to 24 h, followed by: (A) RNA extraction and analysis of HO-1 by qRT-PCR, 
and (B) protein extraction and analysis by immunoblotting for HO-1 and α-tubulin. The histogram shows 
corresponding densitometry data corrected for α-tubulin. Data are expressed as the mean ± SEM (n = 4 
experiments) and normalized to vehicle-treated cells, *P ≤ 0.05, **P ≤ 0.01, using a one-way ANOVA with a 
Bonferonni correction. Immunoblots shown have been cropped to conserve space, please see Supplementary 
file for original uncropped blots.
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is a structural analogue of celecoxib in which the 4-methylphenyl is replaced by a 2,5-dimethylphenyl, so pre-
venting COX-2 inhibition22. The response of HUVEC to DMC mirrored that seen with celecoxib, suggesting 
a COX-2-independent mechanism. Thus, DMC induced a 3–4-fold increase in HO-1 mRNA and protein in a 
concentration-dependent manner (Fig. 2A,B). No HUVEC toxicity was seen with either drug at concentrations 
up to 10 μM, while as expected cell viability began to fall when the concentration of DMC was increased to 30 μM 
(Supplementary Figure 1A,B). Moreover, the presence of cycloheximide attenuated celecoxib-mediated induction 
of HO-1 (p < 0.001), confirming dependence upon de novo protein synthesis (Supplementary Figure 1C).
Naproxen and ibuprofen are two of the most widely prescribed nsNSAIDs. In contrast to celecoxib and DMC, 
they failed to induce HO-1 in HUVEC at concentrations up to 100 μM (Fig. 2C,D). Together these data suggest 
Figure 2. Celecoxib induction of HO-1 is COX-2-independent. HUVEC were treated with 2,5-Dimethyl-
celecoxib (DMC) (up to 10 µM), celecoxib (10 µM) or vehicle alone for 24 h, followed by: (A) RNA extraction 
and analysis of HO-1 by qRT-PCR, and (B) protein extraction and analysis by immunoblotting for HO-1 
and α-tubulin. (C and D) HUVEC were treated with vehicle alone or (C) naproxen, (D) ibuprofen (up to 
100 µM) followed by immunoblotting analysis of HO-1. The histograms show corresponding densitometry 
data corrected for the α-tubulin and normalized to vehicle-treated cells. Data are expressed as the mean ± SEM 
(n = 4 experiments), *P ≤ 0.05, **P ≤ 0.01 using a one-sample t-test (A) and the one-way ANOVA with 
a Bonferonni correction (B–D). Immunoblots shown have been cropped to conserve space, please see 
Supplementary file for original uncropped blots.
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Figure 3. Celecoxib activates AMPK to induce HO-1. HUVECs were treated with: (A) vehicle alone, AICAR 
(1 mM for 24 h) or hemin (0.2 µM for 6 h, positive control), or (B) transfected with Ad0 (control virus), Ad-
CA-AMPK (MOI 100 ifu/cell) or left untreated for 24 h, followed by protein extraction and immunoblotting 
for HO-1 or α-tubulin. (C) HUVECs were treated with celecoxib (10 μM) for up to 60 mins, or (D) naproxen 
up to 100 μM for 15 mins, prior to protein extraction and immunoblotting for phospho-AMPKThr172 and 
GAPDH. (E,F) HUVECs were left untransfected or transfected with control siRNA (CTRL) or AMPKα1 siRNA 
(50 nM) and cultured for 48 h prior to treatment with vehicle or celecoxib (10 µM) for 24 h and (E) analysis 
of HO-1 by qRT-PCR, or (F) protein extraction and immunoblotting for HO-1, total-AMPK and GAPDH. 
Data are expressed as the mean ± SEM of at least 3 separate experiments. The histograms show corresponding 
densitometry data corrected for α-tubulin or GAPDH and normalized to vehicle-treated cells. *P ≤ 0.05, 
**P ≤ 0.01, **P ≤ 0.001, using the one-way ANOVA + Bonferonni correction or a two-way ANOVA. 
Immunoblots shown have been cropped to conserve space, please see Supplementary file for original 
uncropped blots.
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Figure 4. Celecoxib induces HO-1 in HUVEC and HAEC, by activating AMPK and CREB. (A) HUVECs 
were treated with vehicle (veh) or celecoxib (10 μM) for up to 60 mins, prior to lysis and immunoblotting for 
phospho-CREBSer133, total CREB and GAPDH. (B) Nuclear lysates, isolated from HUVEC following treatment 
with celecoxib 10 μM (Cele) or vehicle control for 30 mins, were analysed using a phospho-CREB transcription 
factor assay kit. Unstimulated Hela cells were used as a positive control (CTRL) and a wild-type oligonucleotide 
sequence (WT) was used for competitive binding. CREB-binding is expressed relative to vehicle-treated 
cells. (C,D) HUVECs were left untransfected or transfected with control siRNA (CTRL) or CREB siRNA 
(50 nM) and cultured for 48 h prior to treatment with vehicle or celecoxib (10 µM) for (C) 15 mins followed 
by immunoblotting for phospho-CREB and GAPDH, or for 24 h followed by analysis of (D) HO-1 by qRT-
PCR and (E) HO-1 protein by immunoblotting. (F) HAEC were treated with celecoxib (10 μM) or vehicle for 
15 mins prior to immunoblotting for: phospho-AMPKThr172, phospho-CREBSer133 and GAPDH. (G) HAECs 
were treated with celecoxib (10 μM) or vehicle for 24 h prior to immunoblotting for HO-1. Data are expressed 
as the mean ± SEM of at least 3 separate experiments. The histograms show corresponding densitometry 
data corrected for α-tubulin or GAPDH and normalized to vehicle-treated cells. *P ≤ 0.05, **P ≤ 0.01, 
**P ≤ 0.001, using the one-way with a Bonferonni correction or two-way ANOVA (A–E) and a one-sample 
t-test. (F,G) Immunoblots shown have been cropped to conserve space, please see Supplementary file for 
original uncropped blots.
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Figure 5. Celecoxib activates Nrf2 to induce HO-1 and H-ferritin. (A) HUVECs were left untreated or 
treated with celecoxib (10 μM) for 30 mins prior to fixation and staining with an anti-Nrf2 antibody and 
DRAQ-5 nuclear stain. Representative confocal images are shown along with a histogram representing pooled 
quantification data (n = 4). Data were analysed using Image J software and expressed as mean fluorescent 
intensity (MFI) of Nrf2 staining in the cytoplasm or nucleus. (B) HUVECs were transfected with control siRNA 
(CTRL) or AMPKα1 siRNA (50 nM) and cultured for 48 h prior to treatment with celecoxib and analysis of 
Nrf2 translocation as above. (C,D) HUVECs were transfected with control siRNA or pooled Nrf2 siRNAs 
(40 nM) and cultured for 48 h prior to celecoxib treatment (10 μM for 24 h). Changes in HO-1 were analysed by 
(C) qRT-PCR and (D) immunoblotting and the histogram shows corresponding densitometry data corrected 
for α-tubulin. (E) HUVECs were treated for 24 h with celecoxib or vehicle alone prior to analysis of H-ferritin 
(FHC) mRNA by qRT-PCR. (F–H) HUVECs were transfected with control siRNA or: (F) Nrf2 siRNA. (G) 
AMPKα1 siRNA, (H) CREB siRNA, for 48 h prior to treatment with vehicle or celecoxib and analysis of FHC 
www.nature.com/scientificreports/
7SCIENTIFIC REPORTS |  (2018) 8:6271  | DOI:10.1038/s41598-018-24548-z
that concentrations of celecoxib and DMC up to 10 μM activate a downstream COX-2-independent signalling 
pathway that is not targeted by either naproxen or ibuprofen.
Celecoxib-mediated activation of AMPKα induces endothelial HO-1. Given that AMPK ago-
nist AICAR increased endothelial HO-1 to a level approaching that seen in response to the positive control 
hemin (protoporphyrin IX) (Fig. 3A)23, and in light of our data linking AMPK activation to HO-1 expres-
sion in human EC24, we investigated AMPK as a celecoxib signalling intermediary. First, the 3–4-fold induc-
tion of HO-1 seen in response to AICAR was reproduced by transfection of HUVEC with an adenoviral vector 
expressing constitutively-active AMPK (Fig. 3A,B). Treatment of HUVEC with celecoxib for up to 60 mins led 
to a 2-fold increase in AMPKα activation, as evidenced by phosphorylation at Thr172 which was maximal after 
15 mins (Fig. 3C). Of note, neither exposure to naproxen (Fig. 3D), nor treatment with ibuprofen (Supplementary 
Figure 2A) led to a significant increase in AMPKα phosphorylation.
Next, a loss of function approach using validated siRNA24,25 was adopted to demonstrate the role of AMPKα. 
Exposure of HUVEC to celecoxib for 24 h increased total AMPKα by 70%, while protein expression in untreated 
and celecoxib-treated cells was significantly reduced by AMPKα siRNA (p < 0.001, Supplementary Figure 2B). 
The induction of HO-1 mRNA by celecoxib in EC depleted of AMPKα was completely attenuated (p < 0.001, 
Fig. 3E). Similarly, the increase in HO-1 protein was inhibited by AMPKα silencing, while control siRNA had no 
significant effect (Fig. 3F).
Celecoxib induction of HO-1 involves an AMPK-CREB-dependent pathway. To investigate fur-
ther the transcriptional pathway regulating HO-1 induction by celecoxib, cyclic AMP-response element binding 
protein (CREB) was identified as a potential candidate. CREB activity has been linked positively to vasculopro-
tection26 and CREB is a direct downstream target of AMPK27,28. Treatment of HUVEC with celecoxib resulted 
in a 2–3-fold increase in CREBSer133 phosphorylation after 15–30 mins (Fig. 4A). A DNA-binding ELISA further 
demonstrated CREB activation, with a significant 2-fold increase in CREB DNA binding seen following celecoxib 
treatment and when compared to the vehicle control. The specificity of this response was demonstrated by its 
complete suppression in the presence of a wild-type competitive oligonucleotide corresponding to the CRE con-
sensus sequence (p < 0.01, Fig. 4B).
Silencing AMPKα prior to celecoxib treatment prevented the 3-fold increase in CREB phosphoryla-
tion (p < 0.01), suggesting that AMPKα acts upstream of CREB in HUVEC (Fig. 4C). siRNA oligonucle-
otides were used to demonstrate the functional role of CREB. Celecoxib had no effect on total CREB, while 
CREB-specific siRNA depleted the protein by up to 90% (Supplementary Figure 2). Loss of CREB abrogated the 
induction of HO-1 mRNA and protein by celecoxib (p < 0.01, Fig. 4D,E), further supporting the presence of an 
AMPK-CREB-dependent pathway. Moving away from venous EC, this pathway was also activated in human 
arterial EC (HAEC) following treatment with celecoxib. A 2-fold increase in phospho-AMPKThr172 and a 3-fold 
increase in phospho-CREBSer133 were seen following 15 and 30 mins exposure respectively (Fig. 4F). Likewise, 
treatment of HAEC with celecoxib for 24 h increased HO-1 protein by up to 3-fold (p < 0.001, Fig. 4G).
Nrf2 acts downstream of celecoxib in the vascular endothelium. Transcription factor nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) plays a central role in the regulation of HO-129. Activation of Nrf2 is accompa-
nied by its translocation to the nucleus and binding to anti-oxidant response elements (ARE) in target promoters. 
Nrf2 was confined to the cytoplasm in vehicle-treated HUVEC, while 64.8 ± 4.9% localised to the nucleus following 
treatment with celecoxib (Fig. 5A). Confocal imaging analysis of Nrf-2 nuclear fluorescence intensity confirmed 
that this response was AMPK-dependent, with AMPK silencing significantly attenuating Nrf2 nuclear translo-
cation (p < 0.01, Fig. 5B). Nrf2 siRNA oligonucleotides were able to reduce HUVEC Nrf2 protein by up to 80% 
(Supplementary Figure 2D). Depletion of Nrf2 reduced basal HO-1 mRNA and protein levels and completely abro-
gated the celecoxib-induced increase in HO-1 seen in control siRNA-transfected cells (p < 0.01, Fig. 5C,D).
To explore further the downstream effect of Nrf2 activation by celecoxib, changes in the expression of four 
Nrf2 targets: H-ferritin, NAD(P)H dehydrogenase [quinone] 1 (NQO1); thioredoxin reductase 1 (Txnrd1) and 
thioredoxin were sought. Initial analyses demonstrated differential effects on these target genes with 4-fold and 
1.5-fold increases in H-ferritin and Txnrd1 mRNA levels respectively following celecoxib treatment, and no 
change in either NQO1 or thioredoxin (Supplementary Figure 3A,B and Fig. 5E).
Subsequent experiments utilising control and specific siRNAs confirmed the role of Nrf2 in 
celecoxib-mediated induction of H-ferritin, with complete abrogation of the response following Nrf2 silencing 
(p < 0.01, Fig. 5F). Likewise dependence upon AMPK-CREB signalling was similarly demonstrated (p < 0.01, 
Fig. 5G,H). The role of AMPK, CREB (not shown) and Nrf2 was also confirmed in the more modest induction 
of Txnrd1 (Supplementary Figure 3C,D). Of note, Nrf2 activation alone is not sufficient to activate CREB, as sul-
foraphane treatment failed to induce CREB phosphorylation. In contrast, forskolin treatment, used as a positive 
control activated CREB (Supplementary Figure 3E).
In vivo regulation of HO-1 and H-ferritin in response to celecoxib. To establish whether endothelial 
HO-1 and H-ferritin were altered by celecoxib dosing in vivo, C57Bl/6 mice were fed normal chow or a modified 
mRNA by qRT-PCR. All data are derived from 4 independent experiments, normalized to vehicle-treated cells 
and expressed as the mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, using the two-way ANOVA or a one-
sample t-test. (E) Immunoblots shown have been cropped to conserve space, please see Supplementary file for 
original uncropped blots.
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celecoxib-supplemented chow containing 1000 ppm celecoxib for 48 hours. Selection of the celecoxib concen-
tration in the diet was based on previous studies demonstrating that the mean maximum plasma concentration 
achieved after a single dose of celecoxib in humans (1.53 µg/ml)30 can be achieved in mice receiving this diet31,32. 
Initial experiments confirmed the efficacy of this regimen by measuring serum prostaglandin E2 (PGE2) levels33. 
After 48 hours of celecoxib-treatment the PGE2 serum concentration fell from 107.7 ± 4.6 ng/ml to 60.4 ± 4.2 ng/
ml when compared to control mice (p < 0.05, Supplementary Figure 4A).
Transverse sections of the descending aorta were analysed using confocal immunofluorescence microscopy. 
In the control animals HO-1 was detectable in vascular smooth muscle cells, but not in the aortic endothelium 
of sequential sections in which the endothelium was identified by staining for CD31. In contrast, aortas from 
celecoxib-treated animals showed induction of HO-1 in the CD31+ endothelium lining the descending aorta, 
with an MFI 4-fold higher than untreated controls (p < 0.01, Fig. 6A). Similar experiments were performed using 
an antibody recognising H-ferritin. H-ferritin was barely detectable in the arterial wall of control mice aortas. 
However, in those animals exposed to celecoxib there was a 5–6-fold increase in the expression of H-ferritin in 
the vascular endothelium (p < 0.01, Fig. 6B).
Celecoxib attenuates TNF-α-mediated signalling via AMPK activation and NF-κB inhibition. 
To investigate the COX-2-independent functional effects of celecoxib, HUVEC were treated with celecoxib or 
vehicle for 24 h prior to exposure to TNF-α for 6 h and analysis of VCAM-1 mRNA by qRT-PCR. The marked 
induction of VCAM-1 mRNA by TNF-α was reduced by up to 30% by celecoxib (p < 0.05, Fig. 7A). Similarly 
Figure 6. In vivo dosing of celecoxib upregulates aortic expression of HO-1 and H-ferritin. C57BL/6 female 
mice (n = 4 per group) were fed a diet containing 1000 ppm of celecoxib or matched standard laboratory diet 
for 48 h. Transverse sections of descending aorta were stained with: (A) an anti-HO-1 Ab or (B) an anti-H-
ferritin (FHC) Ab. Anti-CD31 Ab was used to delineate endothelium and nuclei were visualized using DAPI 
nuclear dye. Representative confocal images (x40 magnification) of control and celecoxib-treated mice are 
shown. Histograms (C) HO-1 and (D) FHC show pooled quantification data from 4 independent experiments. 
Images were analysed by ImageJ software. Data are expressed as mean fluorescent intensity (MFI) of endothelial 
fluorescence ± SEM, representing MFI with antibody of interest in celecoxib or vehicle-treated mice divided 
by the MFI obtained with the control Ab and presented normalized to vehicle-treated animals. *P ≤ 0.05, 
**P ≤ 0.01, using an unpaired Student’s t-test. Images shown are at x40 magnification.
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the 15-fold induction in VCAM-1 protein seen after treatment with 0.1 or 1.0 ng/ml TNF-α was significantly 
reduced but not completely abrogated by celecoxib (p < 0.05, Fig. 7B). Treatment with DMC reproduced these 
results, implying that this anti-inflammatory action of celecoxib was independent of COX-2 inhibition (Fig. 7C). 
Moreover, neither naproxen (Fig. 7D) nor ibuprofen (not shown) inhibited TNF-α-mediated induction of 
VCAM-1. Of note, celecoxib treatment predominantly affected VCAM-1, as similar experiments failed to show 
Figure 7. Celecoxib inhibits NF-κB activity to restrict VCAM-1 induction in vascular EC. HUVECs were 
pre-treated with vehicle, (A,B) celecoxib, (C) DMC or (D) naproxen (all 10 µM) for 24 h followed by TNF-α 
stimulation (up to 1 ng/ml) for (A) 6 h, with VCAM-1 analysed by qRT-PCR, and (B,D) 16 h followed by flow-
cytometric analysis of VCAM-1, with data presented as relative fluorescence intensity (RFI), representing mean 
fluorescence intensity (MFI) with the VCAM-1 Ab divided by the MFI of the UT control (n = 4 experiments). 
(E,F) HUVECs were left untreated or treated with celecoxib for 24 h prior to addition of vehicle or TNF-α 
(0.1 ng/ml) for 30 minutes. (E) EC were fixed and stained with an anti-p65 antibody and DRAQ-5 nuclear 
stain. Representative confocal images are shown along with a histogram representing pooled quantification 
data (n = 3 experiments). Data were analysed using Image J software and expressed as the MFI of p65 staining 
in the cytoplasm or nucleus. (F) HUVECs were transfected with control siRNA (CTRL) or Nrf2 siRNA and 
cultured for 30 h prior to treatment with vehicle or celecoxib (10 µM) for 24 h and exposure to TNF-α (0.1 ng/
ml) for 30 mins. Lysates were immunoblotted for phospho-p65Ser536, p65 and GAPDH. The fold change in 
phosphorylation was quantified using densitometry (n = 4 experiments), normalized with respect to GAPDH 
and expressed relative to the vehicle control. Data are expressed as the mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ns = non-significant using one-way or two-way ANOVA. Immunoblots shown have been cropped 
to conserve space, please see Supplementary file for original uncropped blots.
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any significant inhibition of the TNF-α-induced upregulation of the cellular adhesion molecules E-selectin or 
ICAM-1 (Supplementary Figure 4B,C).
To investigate these responses further the impact of Nrf2 activity on the regulation of NF-κB p65 (RelA) was 
explored. As shown in Fig. 7E, TNF-α markedly increased the nuclear localisation of p65 from 3.5 ± 1.3% to 
96.5 ± 1.2%, a response reduced to 34.3 ± 1.5% by celecoxib pre-treatment (p < 0.01). Nuclear translocation of 
p65 follows TNF-α-induced phosphorylation at Ser536, and celecoxib reduced this by up to 50% from 7.72 ± 0.5 
to 4.11 ± 0.5-fold (p < 0.01, Fig. 7F). However, following siRNA silencing of Nrf2 the inhibition by celecoxib was 
attenuated, falling to 23.9% and no longer reached significance Fig. 7F.
In light of the demonstration that AMPK activity can interfere with NF-κB signalling34, its role in the 
anti-inflammatory actions of celecoxib was also explored. In these experiments Compound C proved to be the 
optimal means for inhibition of AMPK. Initial attempts using AMPK siRNA led to variable results between 
experiments. Dosing with Compound C (5 µM) was sufficient to significantly attenuate AMP phosphorylation 
and the protocol used reduced the duration of each experiment leading to improved consistency between exper-
iments. TNF-α increased p65Ser536 phosphorylation by 11-fold and AMPK inhibition increased this by 30%. The 
presence of celecoxib significantly attenuated p65 phosphorylation, reducing it by 55%, a response that was com-
pletely reversed by Compound C (p < 0.01, Fig. 8A).
Turning to the functional consequences of AMPK-mediated inhibition of NF-κB, further experimenta-
tion suggested that activation of AMPK by celecoxib is required for its suppression of VCAM-1 induction by 
TNF-α. VCAM-1 upregulation was suppressed by celecoxib (TNF-α 74.4 ± 2.3- fold and TNF-α + celecoxib 
45.3 ± 1.4-fold) and this change was reversed by Compound C (p < 0.01, Fig. 8B). Although these data are sug-
gestive of a central role for AMPK, Compound C is not specific for AMPK and hence AMPK-independent actions 
cannot be completely excluded35.
Mechanistically, induction of HO-1 was responsible, at least in part, for the inhibition of VCAM-1 by cel-
ecoxib. The induction of VCAM-1 in control siRNA transfected cells was significantly reduced by celecoxib from 
66.2 ± 2.2-fold to 43.4 ± 1.3-fold. However, when HO-1 was silenced the anti-inflammatory action of celecoxib 
was abrogated (Fig. 8C).
To explore the anti-inflammatory actions of celecoxib in the endothelium more widely, the pro-inflammatory 
effect of IL-1β was explored, using induction of IL-6 as an end-point. Treatment of HUVEC with IL-1β resulted 
in a 3-fold increase in IL-6 mRNA. The presence of celecoxib was able to reduce this response by 33% from 
3.20 ± 0.1 to 2.06 ± 0.14-fold (p < 0.05, Fig. 8D). Once again, inhibition of AMPK activity by Compound 
C completely reversed the anti-inflammatory action of celecoxib (IL-1β 3.5 ± 0.13-fold; IL-1β + celecoxib 
2.2 ± 0.16-fold; and IL-1β+ celecoxib + Compound C 3.9 ± 0.17-fold) (p < 0.01, Fig. 8E). Thus, celecoxib acti-
vates an AMPK-CREB-Nrf2-dependent pathway which exerts COX-2-independent anti-inflammatory effects on 
the vascular endothelium through inhibition of TNF-α and IL-1β signalling (Fig. 9).
Discussion
The ability of celecoxib to exert vasculoprotective effects36,37 may reflect in part anti-inflammatory, anti-oxidant 
actions upon macrophages and the vascular endothelium20,21. Activation of PI-3K/Akt, enhanced redox signal-
ling and inhibition of JNK MAPK by celecoxib have been reported18,20,21. By comparing celecoxib with DMC and 
nsNSAIDS, we have now identified further COX-2-independent downstream targets of celecoxib within human 
vascular EC. Celecoxib activates AMPK-CREB-Nrf2-dependent signalling to enhance vascular protection in the 
endothelium via induction of HO-1, H-ferritin and Txnrd1. Single dosing of celecoxib in humans achieves a 
plasma cMax of approximately 2–8 μM30,38. Optimal in vitro responses were seen with 10 μM celecoxib, and this 
may reflect in part the extensive protein binding properties of the drug31. To pursue these observations’ an in vivo 
dosing regimen was chosen that achieves plasma concentrations in mice equivalent to those seen in humans31,32. 
In vivo dosing of celecoxib increased EC expression of both HO-1 and H-ferritin. The novel COX-2-independent 
pathway played a role in the anti-inflammatory actions of celecoxib including suppression of VCAM-1 upregula-
tion by TNF-α, and IL-1β-mediated induction of IL-6.
Concern remains about the atherothrombotic risk associated with the clinical use of anti-inflammatory drugs 
and particularly the COXIBs2. However, nsNSAIDs and COXIBs should be considered as individual agents rather 
than as drug classes. The recently reported SCOT and PRECISION trials found no increased cardiovascular 
risk when comparing celecoxib with nsNSAIDs including naproxen and ibuprofen14,15, while the latest large 
meta-analysis suggests that the inclusion of rofecoxib has skewed the COXIB cardiovascular data8.
We investigated the hypothesis that the differences between the cardiovascular effects of individual nsNSAIDs 
and COXIBs reflect their COX-2-independent actions. The starting point was our observation that while cel-
ecoxib can induce the expression of HO-1 in human endothelium, this response was not seen with rofecoxib20. 
This action of celecoxib allowed direct comparison with DMC, a structural analogue of celecoxib generated to 
lack COX-2 inhibition22. These initial experiments (Figs 1 and 2) revealed directly comparable results between 
celecoxib and DMC in terms of HO-1 induction, so confirming the COX-2-independent nature of the response. 
Furthermore, neither naproxen nor ibuprofen was able to reproduce HO-1 induction.
An emerging relationship between AMPK and Nrf2 led us to explore this pathway in endothelial responses 
to celecoxib. AICAR, berberine and xanthohumol treatment of HUVEC, macrophages or fibroblasts leads to 
AMPK-dependent induction of HO-1 via activation of the transcription factor Nrf223,39,40. Moreover, potent 
anti-inflammatory actions were observed in LPS-treated mice following activation of this pathway by berberine39. 
Celecoxib and DMC treatment of EC led to AMPK activation as evidenced by its phosphorylation at Thr172. In 
contrast, naproxen and ibuprofen failed to activate AMPK. Subsequent loss of function experiments revealed the 
AMPK-dependence of celecoxib-mediated HO-1 induction, Nrf2 activation and nuclear translocation.
AMPK, a heterotrimeric complex that acts as a critical metabolic regulator capable of responding to cel-
lular stress41, plays an important role in endothelial metabolism and homeostasis42. Reduced AMPK activity 
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Figure 8. Celecoxib exerts anti-inflammatory effects via AMPK and induction of HO-1. HUVECs were pre-
treated with Compound C (5 µM) or vehicle alone for 60 mins, prior to addition of celecoxib (10 μM) or vehicle 
for 24 h, followed by: (A) treatment with TNF-α (0.1 ng/ml) or vehicle for 30 mins and immunoblotting for 
p65, phospho-p65Ser536 and GAPDH. The histogram shows corresponding densitometry data for phospho-p65 
corrected for GAPDH, or (B) treatment with TNF-α (0.1 ng/ml) or vehicle for 6 h, and analysis of VCAM-1 
mRNA by qRT-PCR. (C) HUVECs were transfected with HO-1 or control (CTRL) siRNA (40 nM) for 48 h, 
prior to the addition of celecoxib or vehicle for 24 h and treatment with TNF-α (0.1 ng/ml) for 6 h. VCAM-1 
mRNA was analysed by qRT-PCR. (D) HUVECs were left untreated or pre-treated with celecoxib for 24 h prior 
to addition of IL-1β (0.1 ng/ml) or vehicle for 4 h, and (E) HUVECs were left untreated or pre-treated with 
Compound C or vehicle alone for 60 mins, prior to addition of celecoxib for 24 h, followed by IL-1β (0.1 ng/
ml) or vehicle for 4 h. Changes in IL-6 mRNA were analysed by qRT-PCR. Data in the figure are expressed as 
the mean ± SEM of 4 independent experiments and normalized to vehicle-treated cells. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, using one-way ANOVA with a Bonferonni correction. Immunoblots shown have been cropped to 
conserve space, please see Supplementary file for original uncropped blots.
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is associated with oxidative stress and endothelial dysfunction28,42, while selective activation of AMPK in the 
vascular endothelium protects against the harmful effects associated with diabetes mellitus through induction of 
HO-143. Thus, the finding that celecoxib is able to activate both AMPK and Nrf2 brings together redox and meta-
bolic signalling, a combination that may help to minimise cardiovascular risk in patients.
CREB was constitutively expressed in both HUVEC and HAEC and activated by celecoxib as evidenced by 
phosphorylation of Ser133 in its kinase-inducible domain and increased binding to a CRE consensus sequence. 
Silencing of CREB attenuated HO-1 induction by celecoxib. CREB is a direct target of AMPK and its activation 
is considered vasculoprotective. CREB contributes to the regulation of cell metabolism, differentiation and sur-
vival44, and targeted inhibition in the heart predisposes to mitochondrial dysfunction, leading to oxidative stress 
and increased mortality45. Early aortic depletion of CREB is reported in rodent models of vascular disease26.
The combined data suggest that celecoxib has the potential to impart vasculoprotective effects via a COX-
2-independent molecular mechanism comprising 3 signalling components, all of which have their own cytoprotec-
tive actions. Initial investigation of the broader downstream effects of the AMPK-CREB-Nrf2 pathway focused on 
additional Nrf2 targets. Selective effects were seen with H-ferritin, Txnrd1 and HO-1 induced, while there was no 
change in either NQO1 or thioredoxin. This observation may reflect cell-specific effects and/or competition for Nrf2 
binding at individual promoters. The most marked response to celecoxib was seen with HO-1 and H-ferritin and this 
was reproduced in vivo, with a 4-6-fold increase in endothelial expression seen in the murine aorta.
AMPK-Nrf2 signalling has been linked to the regulation of H-ferritin in T lymphocytes46. H-ferritin is widely 
expressed and plays a central role in the handling and storage of intracellular iron47. H-ferritin acts as a catalyst 
for the conversion of Fe2+ to Fe3+ and, along with L-ferritin, exerts an anti-oxidant action by removing excess 
free iron. A close functional relationship exists between H-ferritin and HO-1, including evidence suggesting that 
H-ferritin may on occasion mediate the protective effect of HO-1 against oxidative stress48.
The induction of VCAM-1 by TNF-α was used to initially investigate the functional effects of the celecoxib-activated 
AMPK-CREB-Nrf2 pathway. Pre-treatment with celecoxib or DMC significantly inhibited the induction of VCAM-1. 
However, neither naproxen nor ibuprofen was able to reproduce this effect. Celecoxib attenuated both phosphorylation 
and nuclear translocation of p65 in response to TNF-α. Experiments utilizing Compound C suggested that the inhibi-
tion of NF-κB signalling and IL-1β-mediated induction of IL-6 by celecoxib required activation of AMPK.
The outcome of the interaction between AMPK and NF-κB signalling appears to be context dependent. 
Thus, following activation by celecoxib, AMPK attenuated endothelial NF-κB activation by pro-inflammatory 
cytokines. Metformin is also reported to inhibit TNF-α-mediated activation of NF-κB via AMPK, while similarly 
AMPK activity attenuates fatty acid-induced p65 translocation49,50. In contrast, AMPK activity induced following 
oxygen and glucose deprivation enhanced NF-κB signalling and protected endothelial cells against apoptosis, 
most likely via the induction of Bcl-2 and survivin51. Thus, activation of AMPK may modulate NF-κB signalling 
by switching the binding of p65 and/or recruitment of its co-activators away from pro-inflammatory targets to 
the promoters of anti-inflammatory, anti-apoptotic and anti-oxidant genes. Although the mechanism(s) under-
pinning such responses remains to be established, HO-1 may contribute. The reduction in VCAM-1 upregulation 
Figure 9. Summary of COX-2-independent AMPK-CREB-Nrf2 signalling pathway activated by celecoxib in 
the vascular endothelium. Treatment of human endothelial cells results in COX-2 independent signalling via 
phosphorylation of AMPK at threonine 172 (pAMPK). This leads to activation of CREB at serine 133 (pCREB) 
and nuclear translocation of Nrf2. The CREB and Nrf2 pathways are thought to act in parallel, binding to the 
CREB response element (CRE) and the antioxidant response element (ARE) respectively to upregulate the 
expression of the anti-oxidant, anti-inflammatory genes heme oxygenase-1 (HO-1) and H-Ferritin (FHC). 
The anti-inflammatory actions of this pathway include inhibition of TNF-α-mediated activation and nuclear 
translocation of p65. This response attenuated the pro-inflammatory upregulation of the cellular adhesion 
molecule vascular cell adhesion molecule-1 (VCAM-1).
www.nature.com/scientificreports/
13SCIENTIFIC REPORTS |  (2018) 8:6271  | DOI:10.1038/s41598-018-24548-z
seen in EC pre-treated with celecoxib and exposed to TNF-α was reversed by HO-1 silencing. Moreover, HO-1 
has been reported to inhibit TNF-α-induced activation of NF-κB and adhesion molecule upregulation in EC52,53.
CREB and Nrf2 are members of the bZip family and we have previously suggested that transcriptional 
co-operation might occur between CREB1 and Nrf2 to optimise HO-1 induction54. Similarly heterodimerization 
between Nrf2 and another bZip family member ATF4, facilitates the induction of HO-1 by cadmium chloride55. 
Further experiments sought to investigate whether Nrf2 and CREB were acting in combination. Direct activation 
of Nrf2 in HUVECs with sulforaphane failed to phosphorylate CREB, suggesting that following activation, Nrf2 
and CREB were acting in parallel (Fig. 9). Silencing of Nrf2 partially inhibited celecoxib-mediated inhibition of 
TNF-α-induced p65 phosphorylation. We propose that this is likely, at least in part, to be related to the reduc-
tion in HO-1 seen in Nrf2-depleted cells. Thus, following celecoxib treatment, AMPK phosphorylation leads to 
activation of CREB and Nrf2-dependent pathways that may act in parallel to induce anti-inflammatory genes 
including HO-1 and H-ferritin. Of note, a cAMP/PKA/CREB pathway has been implicated in inhibition of p65 
translocation following treatment with phosphodiesterase antagonists56, while in macrophages Nrf2 specifically 
inhibits inflammation-induced transcription mediated by p6557.
Conclusion
In contrast to ibuprofen and naproxen, celecoxib activates COX-2-independent AMPK-CREB-Nrf2 path-
ways to drive HO-1, H-ferritin and Txnrd1 expression in human EC. This response results in significant 
anti-inflammatory effects including inhibition of TNF-α-mediated NF-κB signalling, and IL-1β induction of 
IL-6. We propose that this and other COX-2-independent actions help to minimise adverse effects in the vas-
culature and contribute to the observation that celecoxib improves endothelial function in those with coronary 
artery disease36 and hypertension37. Recent data suggests that the cardiovascular risk associated with standard 
dose celecoxib is not inferior to nsNSAIDS and that overall risk in patients with arthritis is very low, even in 
those with ischaemic heart disease8,10,11,14,15. In light of this, guidelines should now refocus attention of physi-
cians to consideration of the relative risk of both cardiovascular and gastrointestinal side-effects for each patient 
when prescribing NSAIDs. Additional mechanistic data concerning the vasculoprotective actions of individ-
ual drugs including celecoxib is required and will ultimately lead to development of safer and more effective 
anti-inflammatory therapies.
Materials and Methods
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Reagents and antibodies. Monoclonal antibodies (mAb) against HO-1 and phospho-p65Ser536 
were from Abcam (Cambridge, UK). E-selectin mAb 1.2B6, ICAM-1 mAb 6.5B5 and VCAM-1 mAb 
1.4C3 were generated in house. CD31 mAb P2B1 was generated in house from a clone purchased from 
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA. The following antibodies were 
purchased from Cell Signaling (Danvers, MA) AMPKα, phospho-AMPKαThr172, CREB, phospho-CREBSer133. 
Antibodies against p65 and Nrf2 were from Santa Cruz Biotechnology (Heidelberg, Germany), α-tubulin 
Sigma-Aldrich (Poole, UK) and GAPDH Millipore (Watford, UK). 2,5-Dimethyl-celecoxib was synthesized 
as described58. Celecoxib was purchased from Toronto Research Chemicals (Ontario, Canada), naproxen 
and ibuprofen from Tocris Bioscience (Bristol, UK). The concentrations of all three drugs used in vitro 
(celecoxib 1–10 µM, naproxen and ibuprofen 1–100 μM) included concentrations that can be achieved thera-
peutically in humans30,38,59,60. 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and Compound C 
were from Millipore, hemin and sulforaphane from Sigma-Aldrich, TNFα and IL-1β from R and D Systems 
(Abingdon, UK).
Endothelial cells. Use of human EC was approved by Hammersmith Hospitals Research Ethics Committee 
(ref no. 06/Q0406/21). Informed consent was obtained and all experiments were performed in accordance with 
relevant guidelines and regulations. Human umbilical vein endothelial cells (HUVEC) were isolated by colla-
genase Type II digestion. Human aortic EC (HAEC) were purchased from Promocell, (Heidelberg, Germany). 
HUVEC and HAEC were propagated in M199 medium supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin, 20% FCS, and 30 μg/ml heparinized endothelial cell growth factor (ECGF) (all from 
Sigma-Aldrich). Experiments were performed with passage 3–5 EC from at least three separate isolates, plated 
in M199/2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 10% FCS, and 7.5 μg/ml ECGF. Pharmacological 
antagonists were added to the endothelial culture medium 30–60 min before celecoxib.
Cell viability assay. HUVECs monolayers were treated with celecoxib, DMC or vehicle for 24 h. Cell viabil-
ity was analysed by incubation with 20% 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
in a growth factor-free medium for 3 h. Plates were read on a Synergy HT plate reader and the number of viable 
cells determined by measuring the absorbance at 490 nm.
siRNA Transfection. GeneFECTOR (3:50) (VennNova, Parkland Fl) and siRNA (40 nM final) were diluted 
in Opti-MEM I (Invitrogen, Paisley, UK) and equal volumes of each were mixed and incubated at r/t for 5 min. 
siRNA complexes were added drop wise to HUVECs cultured in Opti-MEM I medium. After incubation for 4 h, 
culture medium was replaced with EGM2 medium (Lonza, Wokingham, UK) overnight and subsequently by 
M199/10% FCS. The following validated siRNA oligonucleotides were employed24,54,61.
HO-1 (siHO-1 seq. 2) 5′- AACAUUGCCAGUGCCACCAAG-3′ (Qiagen, Manchester, UK).
AMPKα1 siRNA (Hs_PRKAA1_5) 5′-CCCACGATATTCTGTACA CAA-3′ (Qiagen).
CREB-1 pooled sequences (Dharmacon, Epsom, UK):
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5′-GAGAGAGGTCCGTCTAATG-3′; 5′-CGTACAAACATACCAGATT-3′;
5′-GAGTGGAGATGCAGCTGTA-3′; 5′-TGACTTATCTTCTGATGCA-3′.
Nrf2 pooled sequences (Dharmacon):
5′-TGACAGAAGTTGACAATTA-3′; 5′-TAAAGTGGCTGCTCAGAAT-3′
5′-CCAAAGAGCAGTTCAATGA-3′; 5′-GAGAAAGAATTGCCTGTAA-3′.
The si-GENOME Non-Targeting siRNA #1 from Dharmacon containing 4 mismatches to any human, mouse 
or rat gene was used as a negative control.
Quantitative real-time PCR. Quantitative real-time PCR (qRT-PCR) was performed using the CFX96 
Real-Time system and C1000 Thermal cycler (Bio-Rad, Hercules, CA), with data calculated in relation to house-
keeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). RNA was extracted from 
HUVEC using the RNeasy mini kit (Qiagen) and quantified at 260/280 nm using a Nanodrop 2000 spectro-
photometer (Thermo Scientific, UK). 1 μg of DNase-1-digested total RNA was reverse transcribed into cDNA 
using 1 μM oligo(dT) and Superscript reverse transcriptase (Invitrogen, Paisley, UK). cDNA was amplified in 
a 25 μl reaction solution containing 5 μl of cDNA template, 12.5 μL of iSYBR supermix, 0.5 pM sense and 
antisense gene-specific primers, and double distilled water (dd H2O). The cycling parameters were 5 min at 
94 °C, 35 cycles at 95 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec. The primer sequences used are listed in 
Supplementary Table 1.
Adenoviral infection. Adenoviruses encoding constitutively-active AMPK (AdCA-AMPK) (a gift from 
David Carling, Imperial College London) or green fluorescent protein (Ad-GFP) were amplified in HEK293A 
cells. Virus particles were purified according to manufacturers’ instructions using the AdEasyTM Virus 
Purification Kit (Stratagen, La Jolla, CA). Titrations were performed using the Adeno-XTM Rapid Titer Kit 
(Clontech Laboratories Inc., Mountain View, CA). Following optimisation experiments, HUVECs were infected 
at a multiplicity of infection (MOI) of 100 viral particles/cell in plain M199 at 37 °C for 2 h. The cells were then 
cultured for 24 h in M199/10% FCS and 7.5 μg/mL ECGF.
CREB activation assay. A CREB (Phospho-Ser133) transcription factor assay kit (Cayman Chemicals, 
Cambridge, UK) was used to determine the transcriptional activation of CREB as per the manufacturers’ instruc-
tions. Nuclear extracts (10 μg) were added to a 96-well plate pre-coated with a specific double-stranded DNA 
(dsDNA) consensus sequence containing the cAMP response element (CRE) and incubated for 1 h at r/t. A 
wild-type oligonucleotide was used as a binding competitor. Unstimulated Hela nuclear extract was used as a 
positive control. The primary antibody was directed against phospho-CREB Ser133 and an HRP-conjugated sec-
ondary Ab was added to provide a sensitive colorimetric read-out at 450 nm
Immunoblotting. EC were lysed in RIPA buffer (Sigma-Aldrich), containing a complete phosphatase and 
protease inhibitor (Roche, Burgess Hill, UK) at 4 °C for 15 minutes. 15 μg of protein was mixed with 7.5 μl of 
4x NuPAGE® LDS Sample Buffer (Invitrogen) and 2 μl of DL-Dithiothreitol Solution (Sigma), and the sam-
ple boiled, prior to SDS-PAGE separation and transfer onto polyvinylidene difluoride membranes (Millipore, 
Massachusetts) using a semi-dry blotting apparatus (Bio-Rad). Membranes were blocked with 5% BSA and 
incubated with primary antibodies overnight at 4 °C. Following washing, membranes were incubated with a 
horseradish-peroxidase-conjugated secondary Ab diluted in 5% BSA, washed and developed using chemilumi-
nescence ECL plus (GE Healthcare, UK) and exposed to Biomax light film (Kodak, Watford, UK). Densitometry 
of the protein bands was performed using ImageJ v1.45 Software (National Institute of Health, USA) and 
expressed relative to housekeeping proteins α-tubulin and GAPDH.
Flow cytometry. HUVEC were harvested and resuspended in HBSS/1% FCS and stained with primary 
antibodies for 30 mins at 4 °C. The cells were washed, centrifuged and stained with FITC-labelled polyclonal 
anti-mouse IgG (DAKO, Stockport, UK) for 30 min at 4 °C. Following washing and resuspension in PBS, 10,000 
cells were analysed using a CyAn™ ADP Analyzer (Beckman Coulter, Luton, UK) with Summit 4.3 software used 
to process data. Results are expressed as the relative fluorescent intensity, representing mean fluorescent intensity 
(MFI) with test monoclonal antibody divided by the MFI using the secondary antibody alone.
Nuclear translocation studies. HUVECs were fixed in ice-cold methanol for 10 min, blocked with 
PBS/5% BSA and incubated at 4 °C overnight with rabbit anti-Nrf2 (1:200), rabbit anti-p65 (1:200) or negative 
control rabbit Ig fraction (DAKO), followed by washing and addition of either AlexaFluor goat anti-rabbit 488 
(Invitrogen) or AlexaFluor donkey anti-rabbit 594 (Invitrogen) for 1 h at room temperature. Slides were washed, 
stained with Draq5 and mounted using Vectashield (Vector Laboratories, Peterborough, UK). Nuclear translo-
cation was analysed using a Zeiss LSM META confocal microscope, with images obtained at 40× magnification 
from ten random fields of view. Fluorescence intensity of Nrf2 and p65 was quantified after correction for auto-
fluoresence and defining threshold intensity from background fluorescence.
Animals. Mice were housed in microisolator cages under controlled climactic conditions with autoclaved 
bedding. Irradiated food and drinking water were freely available. All animals were studied according to the 
guidelines from Directive 2010/63/EU of the European Parliament, with ethical approval from Imperial College 
London under UK Home Office Licence number PPL 70/7555. Female 8 week old C57BL/6 mice were fed for 
48 hours on the standard laboratory diet (Harlan Teklad Global 18% Protein Rodent Diet, 2018) a modified 
celecoxib-supplemented form of the diet containing 1000 ppm celecoxib (Harlan) for 48 hours32. This dosing 
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regimen achieves a plasma concentration of celecoxib in mice that is equivalent to the mean plasma concentra-
tion in humans following a single dose of celecoxib (1.53 µg/ml)30,32. Following treatment, mice were sacrificed 
by CO2 inhalation followed by cervical dislocation. Murine descending aorta was embedded vertically in OCT 
Embedding Matrix (CellPath Ltd, Newton, UK) and snap frozen in supercooled methylbutane (Sigma-Aldrich). 
5 µm cryostat sections (Leica Microsystems, Wetzlar, Germany) were mounted on Superfrost microscope slides 
(Thermo Scientific, Waltham, MA), air-dried, fixed in ice-cold acetone for 5 minutes and stored at −80 °C.
Prostaglandin E2 ELISA. The Prostaglandin E2 ELISA kit was from Arbor Assays (Ann Arbor, MI). 500 µl 
of blood was obtained from the sacrificed animals through cardiac puncture. The blood was left to coagulate 
for 2 h at 4 °C and then centrifuged at 14000 rpm for 15 mins. Serum was aspirated, re-centrifuged for 5 mins at 
14000 rpm prior to storage at −80 °C. Samples were diluted 1:20 in assay buffer and analysed in duplicate accord-
ing to the manufacturers’ instructions and read at 450 nm on a Synergy HT plate reader (Bio Tek Instrument, 
Swindon, UK).
Immunohistochemistry. Transverse sections of frozen aorta were blocked for 1 h with 20% goat serum or 
20% rabbit serum (DAKO) diluted in PBS. Polyclonal goat anti-mouse HO-1 or goat IgG isotype control (Santa 
Cruz) diluted 1:100 in PBS were added and incubated overnight at 4 °C. The process was repeated with poly-
clonal rabbit anti-mouse H-ferritin (Abcam, US) or rabbit IgG isotype control (Santa Cruz). Following washing, 
Alexa Fluor 568-conjugated rabbit anti-goat IgG or Alexa Fluor 546-conjugated goat anti-rabbit IgG (Invitrogen) 
(1:200) were added for 1 h in the dark. Slides were washed in PBS and rat anti-mouse CD31 mAb (Biolegend, SD, 
USA) was added as an endothelial marker and incubated for 2 h in the dark. Slides were washed and incubated 
with Alexa Fluor 488-conjugated goat anti-rat IgG and DAPI (4′6′-diamidino-2-phenylindole, Sigma) for 60 
and 5 min respectively. Slides were mounted in Vectashield (Vector) and images captured with a Leica DM 2500 
fluorescent microscope (Leica Microsystems, Wetzlar, Germany). Negative control area images were used in the 
calibration of green or red channel background intensity. Scan settings were set to optimise the signal/noise ratio 
for each emission wavelength. There was no detectable crossover between channels. Leica LAS EZ version 4.3 
software was used to process the images which were quantified using ImageJ. Endothelial and adventitial areas 
were identified using the anti-CD31 stained co-localised image. Next, HO-1 and H-ferritin levels were quantified 
by recording the mean fluorescence intensity in the specific areas. The distribution of the pixel intensities in the 
red and green channels was computed using the histogram function. The background signal from the negative 
control images was subtracted.
Statistical analysis. Data were analysed using GraphPad Prism Software (San Diego, CA, USA). Numerical 
data are presented as the mean of at least 3 individual experiments ± standard error (SEM). As indicated in the 
figure legends, differences between treatments were evaluated using the following methods: a one-sample t-test to 
compare two columns, an unpaired Student’s t-test, Mann-Whitney U test or, to evaluate three or more samples, 
the analysis of variance (ANOVA) was used. A Bonferroni correction was used to correct for multiple compari-
sons. P < 0.05 was considered significant.
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